Qinglin Tang

State Key Laboratory Of Anti Infective Drug Discovery And Development
Guangzhou, 510006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Structure-Based Development of a Novel Macrocyclic Peptide to Disrupt the Lumican-Collagen I Interaction in Liver Fibrosis.

Structure-Based Development of a Novel Macrocyclic Peptide to Disrupt the Lumican-Collagen I Interaction in Liver Fibrosis.

Journal: Journal of medicinal chemistry

Published: November 28, 2025

Methanol-driven co-metabolic enhancement of benzotriazole and 5-chlorobenzotriazole degradation by Chlorella pyrenoidosa: Mechanisms, transformation pathways, and metabolic insights.

Methanol-driven co-metabolic enhancement of benzotriazole and 5-chlorobenzotriazole degradation by Chlorella pyrenoidosa: Mechanisms, transformation pathways, and metabolic insights.

Journal: Journal of hazardous materials

Published: June 13, 2025

Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis.

Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis.

Journal: Journal of medicinal chemistry

Published: May 05, 2025

A metabolic enzyme-photosynthetic machinery involved in the co-metabolism of enrofloxacin and ciprofloxacin by Chlorella pyrenoidosa.

A metabolic enzyme-photosynthetic machinery involved in the co-metabolism of enrofloxacin and ciprofloxacin by Chlorella pyrenoidosa.

Journal: Journal of hazardous materials

Published: January 23, 2025

Co-metabolism of Norfloxacin by Chlorella pyrenoidosa: Carbon source effects, biotransformation mechanisms, and key driving genes.

Co-metabolism of Norfloxacin by Chlorella pyrenoidosa: Carbon source effects, biotransformation mechanisms, and key driving genes.

Journal: Journal of hazardous materials

Published: September 27, 2024

Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis.

Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis.

Journal: Journal of medicinal chemistry

Published: July 11, 2024

Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells.

Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells.

Journal: Acta pharmaceutica Sinica. B

Published: April 11, 2024

Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment.

Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment.

Journal: Journal of medicinal chemistry

Published: April 08, 2024

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment.

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment.

Journal: Journal of medicinal chemistry

Published: June 06, 2023

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis.

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis.

Journal: Journal of medicinal chemistry

Published: March 20, 2023

Visible-Light-Driven Redox Neutral Direct C-H Amination of Glycine Derivatives and Peptides with N-Acyloxyphthalimides.

Visible-Light-Driven Redox Neutral Direct C-H Amination of Glycine Derivatives and Peptides with N-Acyloxyphthalimides.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: June 06, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026